Literature DB >> 21374098

[Patient pathways in thrombosis prophylaxis after hip and knee replacement surgery : results of a survey].

S Müller1, T Wilke, M Pfannkuche, I Meber, A Kurth, H Merk, F Steinfeldt, D Ganzer, C Perka.   

Abstract

A key element of patient care after hip and knee replacement is medication-based thrombosis prophylaxis. Due to decreasing lengths of acute hospital stays the question arises to what extent outpatients are taking responsibility thrombosis prophylaxis (patient pathway analysis).To analyze patient pathways a telephone survey of 668 patients was conducted. On average patients were interviewed 38 days following surgery with a focus on low molecular weight heparins. The analysis showed that nearly 90% of patients need to carry out thrombosis prophylaxis in an outpatient or home environment for at least 1 day and for 47.2% of patients a linking period between acute and rehabilitation stay is relevant. The obviously existing quantitative importance of outpatient thrombosis prophylaxis is also reflected by its duration and 45.7% of interviewed patients needed at least 5 days of outpatient prophylaxis.Outpatient thrombosis prophylaxis clearly makes high demands on the patients, in particular when combined with the task of administering complex forms of injections. Those involved in inpatient and outpatient provision of care should not assume that all patients carry out the necessary prophylaxis at the required level of reliability. On the contrary initial evidence shows that the non-adherence of patients during ambulatory thrombosis prophylaxis presents a genuine challenge to care providers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21374098     DOI: 10.1007/s00132-011-1741-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  12 in total

Review 1.  Anticoagulation: the present and future.

Authors:  H Van Aken; C Bode; H Darius; C Diehm; A Encke; D C Gulba; S Haas; W Hacke; W Puhl; M Quante; H Riess; R Scharf; S Schellong; T Schrör; K L Schulte; U Tebbe
Journal:  Clin Appl Thromb Hemost       Date:  2001-07       Impact factor: 2.389

2.  Patient preferences for an oral anticoagulant after major orthopedic surgery: results of a german survey.

Authors:  Thomas Wilke
Journal:  Patient       Date:  2009-03-01       Impact factor: 3.883

3.  Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery.

Authors:  Thomas Wilke; Jörn Moock; Sabrina Müller; Matthias Pfannkuche; Andreas Kurth
Journal:  Clin Orthop Relat Res       Date:  2010-03-24       Impact factor: 4.176

4.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Authors:  B I Eriksson; O E Dahl; H R Büller; R Hettiarachchi; N Rosencher; M-L Bravo; L Ahnfelt; F Piovella; J Stangier; P Kälebo; P Reilly
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

Review 5.  [Prevention of thrombosis in hip prosthesis implantation].

Authors:  F Böttner; T P Sculco; N E Sharrock; G H Westrich; J Steinbeck
Journal:  Orthopade       Date:  2001-11       Impact factor: 1.087

Review 6.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 7.  Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Authors:  Sean T Duggan; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  James D Douketis; Peter B Berger; Andrew S Dunn; Amir K Jaffer; Alex C Spyropoulos; Richard C Becker; Jack Ansell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  [Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals].

Authors:  T Wilke; K Neumann; U Klapper; I Messer; A Werner; U Seidel; D Röleke
Journal:  Orthopade       Date:  2008-05       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.